Evidence map›Paper›PMID 39757510›Full record

ArticleFEBS letters2025

Ligand recognition by 14-3-3 proteins requires negative charges but not necessarily phosphorylation.

Seraphine Kamayirese, Laura A Hansen, Sándor Lovas

Abstract read
In one paragraph

Article in FEBS letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Seraphine KamayireseDepartment of Biomedical Sciences, Creighton University, Omaha, NE, USA.
Laura A HansenDepartment of Biomedical Sciences, Creighton University, Omaha, NE, USA.
Sándor LovasDepartment of Biomedical Sciences, Creighton University, Omaha, NE, USA.ORCID 0000-0002-5089-5186

Funding

Understanding the progression of hearing loss in an endolymphatic hydrops modelP20GM139762 · NIGMS · CREIGHTON UNIVERSITY · PI Hui Hong · 2021 to 2026
$16.1M
Targeting aberrant anti-apoptotic signaling for prevention of skin cancerR01CA253573 · NCI · CREIGHTON UNIVERSITY · PI HANSEN, LAURA A · 2020 to 2024
$1.6M
NCI NIH HHS R01 CA253573NIGMS NIH HHS P20 GM139762NIH HHS 5P20GM139762NIH HHS R01 CA253573-01State of Nebraska LB 595
6 · The paper itself

Abstract

Protein-protein interactions involving 14-3-3 proteins regulate various cellular activities in normal and pathological conditions. These interactions have mostly been reported to be phosphorylation-dependent, but the 14-3-3 proteins also interact with unphosphorylated proteins. In this work, we investigated whether phosphorylation is required, or, alternatively, whether negative charges are sufficient for 14-3-3ε binding. We substituted the pThr residue of pT(502-510) peptide by residues with a varying number of negative charges and investigated the binding of the peptides to 14-3-3ε using MD simulations and biophysical methods. We demonstrated that at least one negative charge is required for the peptides to bind 14-3-3ε, although phosphorylation is not necessary, and that two negative charges are preferable for high affinity binding. This discovery opens up new approaches for designing peptide-based 14-3-3 protein inhibitors.

Indexed as

14-3-3 ProteinsPeptidesBinding SitesHumansLigandsMolecular Dynamics SimulationPhosphorylationProtein Binding14-3-3 ProteinsLigandsPeptides14‐3‐3 proteinsbinding motifphosphate mimicsphosphopeptides

Identifiers

PMID39757510
PMCPMC11931987

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.